T-Cell Therapy Market by Type of Therapy (CAR-T, TCR and TIL), Target Indication, Target Antigen (BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and Others), Company Size (Small, Mid-sized and Large), Geographical Regions (

T-CELL THERAPY MARKET

As per Roots Analysis, the global T-cell therapy market size is estimated to grow from USD 6.5 billion in the current year to USD 20.9 billion by 2035, at a CAGR of 12% during the forecast period, till 2035.

The opportunity for the T-cell therapy market has been distributed across the following segments:

Type of Therapy

CAR-T

TCR

TIL

Target Indication

Multiple Myeloma

Large B-Cell Lymphoma

Acute Lymphoblastic Leukemia

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Follicular Lymphoma and High grade B-cell lymphoma

Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Acute Myeloid Leukemia

Generalized Myasthenia Gravis (MG)

Renal transplantation (HLA-A2)

Gastric Adenocarcinoma

Ovarian / Endometrial Cancer

Chronic Lymphocytic Leukemia

Follicular Lymphoma

Renal Cell Carcinoma

Melanoma

Basal Cell Carcinoma

Lung Cancer

Sarcoma

Head And Neck Cancer

Cervical Cancer

Neuro Gastro-Intestinal (GI) Cancer

Breast Cancer

Hepatocellular Carcinoma

Nasopharyngeal Carcinoma

Ovarian Cancer

Target Antigen

BCMA

CD19

CD20

CD19, CD22

HLA

MAGE

PRAME

NY-ESO-1 and LAGE

EBV

HBV

Others

Company Size

Small

Mid-sized

Large Research

Geographical Regions

North America

Europe

Asia-Pacific

Latin America

Middle East and North Africa

Rest of the World

T-CELL THERAPY MARKET: GROWTH AND TRENDS

T cells, a subset of white blood cells, are essential to the immunological system of the human body. The body’s reactions to external allergens and infections are tightly controlled by these cells, which efficiently identify, target, and eliminate them while recalling the first interactions to trigger a prompt and efficient immune response. Scientists have been actively researching these cells since the 19th century with an aim to leverage them to treat a wide range of medical conditions. In fact, cell therapies (specifically T cell therapies) have attracted a lot of attention lately for managing / treating hard-to-treat diseases, like cancer, autoimmune diseases, and uncommon genetic disorders, ultimately decreasing the global disease burden.

Cancer is one of the leading causes of mortality, accounting for 0.6 million deaths in 2022, in the US alone. As per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Although cancer therapeutics continue to be one of the most active areas, in terms of drug development, there are several persistent challenges in this domain. In fact, conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers.

Amidst the ongoing efforts to develop more precise and effective anti-cancer therapeutics, T-cell therapies have evolved as a promising immunotherapy that uses the body’s own immune cells to selectively eliminate tumor cells with minimal side effects. Unlike conventional therapies, immunotherapies provide several advantages, including specificity, potential reduction in off-target toxicities and improving treatment outcomes. It is worth mentioning that in 2024, the US Food and Drug Administration approved multiple T cell therapies targeting cancer (in reverse chronological order), such as Obecabtagene autoleucel / Aucatzyl (relapsed or refractory B-cell precursor acute lymphoblastic leukemia, November 2024), Afamitresgene autoleucel / TECELRA (metastatic or unresectable synovial sarcoma, August 2024) and Lifileucel / Amtagvi (unresectable or metastatic melanoma, February 2024).

Driven by the advantages offered by immunotherapies over conventional therapies, the increasing adoption of T-cell-based immunotherapies and the surge in demand for personalized cancer treatment, coupled with the expedited regulatory approvals, is expected to drive significant growth in the T cell therapeutics market. Moreover, as the global oncology landscape continues to evolve, advancements in T cell engineering and next-generation manufacturing technologies would drive innovation in this domain and position the market for steady growth in the forthcoming years.

T-CELL THERAPY MARKET: KEY INSIGHTS

The report delves into the current state of the T cell therapy market and identifies potential growth opportunities within industry. Some key findings from the report include:

With over 10 approved therapies and more than 1,200 preclinical / clinical therapy candidates, CAR-T immunotherapies represent one of the most active segments of the pharmaceutical domain.

More than 75% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature; notably, CD19 and BCMA have emerged as the most popular target antigens.

Presently, there are over 205 TCR-based therapies that are approved / under clinical stages of development; notably, the current landscape is dominated (38%) by mid-sized players based in Europe.

Close to 35% of the TCR immunotherapies in the clinical development pipeline are being developed to target oncological disorders in adults, children and senior citizens.

Over 85 TIL-based immunotherapies have been either approved or are currently under development; of these, most of the immunotherapies are being developed by players based in North America to target melanoma.

Majority (58) of the TIL-based therapies are being used in combination with various therapeutic agents; of these, more than 45% of the immunotherapies are being developed by non-industry players.

Extensive efforts are underway to improve the CAR constructs across successive generations, involving alterations in the scFv region and using different types of gene delivery vectors.

In the last few years, over 970 clinical trials have been registered across different geographies for CAR-T therapies; extensive efforts are underway to improve successive generations of therapies.

The growing interest of stakeholders is evident from the increasing partnership activity in this domain; close to 45% of the total number of partnerships have been signed between players based in North America.

Several investors, having realized the opportunity within this upcoming segment of cancer immunotherapy, have invested more than USD 32 billion, across 370+ funding rounds in the past few years.

More than 11,900 patents related to CAR-T cell therapies have been filed / granted to protect the intellectual property generated within this field.

Apart from CAR-T, TCR and TIL-based products, close to 205 other T-cell immunotherapies are marketed / under development for the treatment of a myriad of oncological and non-oncological indications.

Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development.

Given the growing prevalence of cancer, technological developments and ongoing approvals, the market for T-cell therapies is poised to witness a steady growth in the foreseen future.

With a growing focus on the development pipeline and encouraging clinical trial outcomes, the market is expected to witness an annualized growth rate of over 12%, during the next decade.

T-CELL THERAPY MARKET: KEY SEGMENTS

CAR T-cell Therapy Market Holds the Largest Share of the T-Cell Therapy Market During the Forecast Period

Based on the type of therapy, the global market is segmented into CAR-T, TCR and TIL therapies. Currently, the CAR T-cell therapy market segment captures the majority of the overall market share and is likely to dominate and drive the overall market growth. This can be attributed to the precise targeting mechanism of CAR T cell therapies that use chimeric antigen receptors to target and kill malignant cells (while minimizing damage to healthy tissues). It is worth highlighting that the TIL therapy market segment is likely to flourish during the forecast period, owing to their versatility in targeting a wide range of cancers and encouraging clinical trial results.

Therapies Targeting Melanoma Hold the Largest Share of TCR Therapies Market

Based on the target indication, the T-cell therapy market is segmented into multiple myeloma, large B-cell lymphoma, acute lymphoblastic leukemia, diffuse large b-cell lymphoma, diffuse large b-cell lymphoma, primary mediastinal large B-Cell lymphoma, transformed follicular lymphoma and high grade B-cell lymphoma, acute lymphoblastic leukemia / B-cell Non-Hodgkin lymphoma, Non-Hodgkin lymphoma, mantle cell lymphoma, acute myeloid leukemia, generalized myasthenia gravis (MG), renal transplantation (HLA-A2), gastric adenocarcinoma, ovarian / endometrial cancer, chronic lymphocytic leukemia, follicular lymphoma, renal cell carcinoma, melanoma, basal cell carcinoma, lung cancer, sarcoma, head and neck cancer, cervical cancer, neuro gastro-intestinal (GI) Cancer, breast cancer, hepatocellular carcinoma, nasopharyngeal carcinoma and ovarian cancer.

Currently, the majority share of the TCR therapies market is captured by therapies targeting melanoma (over 95%). This can be attributed to the fact that melanoma has a high rate of genetic mutations, leading to the production of many unique neoantigens which makes it a prime target for TCR therapies. Recently, the FDA has approved a TCR therapy (Kimmtrak) which is used to treat adults with metastatic uveal melanoma (a type of intraocular melanoma).

Therapies Targeting CD19 Antigen are Likely to Dominate the CAR-T Therapy market During the Forecast Period

Based on the type of target antigens, the T-cell therapy market is segmented into BCMA, CD19, CD20, CD19 and CD22, HLA, MAGE, PRAME, NY-ESO-1 and LAGE, EBV, HBV and others. Currently, therapies targeting CD19 antigen dominate the CAR-T therapies market, accounting for more than 65% of the overall market share. This dominance is primarily driven by the essential role of CD19 as it is a highly specific antigen expressed on B-cells, making it an ideal target for treating B-cell malignancies like leukemia and lymphoma.

North America Accounts for the Largest Share of the overall TCR therapy Market

Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa, and the rest of the world. In the current scenario, North America is likely to capture the largest market share owing to the robust research and development infrastructure, a strong commercial base for cell therapies, and a high number of clinical trials being conducted in the region.

However, it is worth noting that the market for TCR therapies in Asia-Pacific is expected to grow at a relatively faster pace (CAGR of more than 45%), during the forecast period. This is driven by the increasing cases of cancer in the region, supported by the demand for curative treatments. Notably, it has been highlighted by industry experts that the cell therapy industry in China has witnessed growing interest from investment firms, enabling faster clinical research for T-cell therapies.

Example Players in the T-Cell Therapy Market

Adaptimmune Therapeutics

AbelZeta

Alaunos Therapeutics

Autolus Therapeutics

bluebird bio

Bristol Myers Squibb

CARsgen Therapeutics

Cellectis

Gilead Sciences

Immatics

Immunocore

Innovative Cellular Therapeutics

Iovance Biotherapeutics

Kuur Therapeutics

Lion TCR

Noile-Immune Biotech

Novartis

Takara Bio

Wellington Zhaotai Therapies

Zelluna immunotherapy

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, Mid-sized Company, China

Chief Operating Officer and Executive Vice President, Small Company, France

Former Co-Founder and Chief Executive Officer, Mid-sized Company, UK

Former Chief Executive Officer, Small Company, Netherlands

Former Chief Executive Officer, Mid-sized Company, Australia

Former Vice President, Immuno-Oncology, Mid-sized Company, Belgium

Director, Business Development, Small Company, US

Former Director, Process Development, Large Company, US

Former Research Head, Large Company, US

Former Competitive Intelligence Manager, Strategy & Business Development, Small Company, US

Professor of Medicine and Director, Department of Oncology, Hospital, China

Assistant Professor of Medicine, University, US

T-CELL THERAPY MARKET: RESEARCH COVERAGE

The report on T-cell therapy market features insights into various sections, including:

Market Sizing and Opportunity Analysis: An in-depth analysis of T-cell therapy market, focusing on key market segments, including [A] type of therapy, [B] target indication, [C] target antigen, [D] company size, [E] geographical regions, [F] leading players, and [G] sales forecast (of more than 55 T-cell therapies).

CAR-T cell therapies Market Landscape: A comprehensive evaluation of CAR-T cell therapies, based on several relevant parameters, such as [A] type of developer, [B] stage of development, [C] therapeutic area, [D] target indication, [E] target antigen, [F] source of T-cells, [G] route of administration, [H] dosing frequency, [I] patient segment, [J] type of therapy, [K] most active industry players, and [L] most active non-industry players.

CAR-T cell therapies Developer Landscape: The report features a list of players engaged in the development of CAR-T cell therapies offered, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters.

TCR-based therapies Market Landscape: A comprehensive evaluation of TCR-based therapies, based on several relevant parameters, such as [A] stage of development, [B] therapeutic area, [C] target indication, [D] target antigen, [E] source of T-cells, [F] route of administration, [G] dosing frequency, [H] target patient segment, [I] type of therapy, [J] most active industry players, and [K] most active non-industry players.

TCR-based therapies Developer Landscape: The report features a list of players engaged in the development of TCR-based therapies offered, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters.

TIL-based therapies Market Landscape: A comprehensive evaluation of TIL-based therapies, based on several relevant parameters, such as [A] type of developer, [B] stage of development, [C] route of administration, [D] dosing frequency, [E] patient segment, [F] type of therapy, [G] most active industry players, and [H] most active non-industry players.

TIL-based therapies Developer Landscape: The report features a list of players engaged in the development of TIL-based therapies offered, along with analyses based on [A] year of establishment, [B] company size, and [C] location of headquarters.

Key Insights Analysis: An in-depth analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies, based on various relevant parameters, such as [A] generation of CAR, [B] type of binding domain, [C] type of virus used, [D] type of gene transfer method used, and [E] type of co-stimulatory domain used.

Clinical Trial Analysis: A detailed analysis of completed, ongoing, and planned clinical studies related to CAR-Ts, TCRs, and TIL, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial recruitment status, [D] trial phase, [E] target patient segment, [F] type of sponsor/collaborator, [G] most active players, and [H] regional distribution of trials.

Key Opinion Leaders (KOLs) Analysis: A comprehensive evaluation of various principal investigators (considered as key opinion leaders in this domain) involved in clinical trials related to CAR-Ts, TCRs and TILs. The section presents detailed analyses, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Therapy Profiles: Elaborate profiles of marketed and mid- to late-stage clinical therapies (phase I / II or above) related to CAR-Ts, TCRs and TILs, providing insights on [A] overview of the therapy, [B] mechanism of action of therapy, [C] dosage information, [D] details on the cost, and sales information (wherever available), [E] clinical development plan, and [F] key clinical trial results.

Emerging Technologies: A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as [A] ease of system design, [B] cost of technology, [C] level of toxicity, and [D] efficiency of technology.

Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in T-Cell therapy market, based on several parameters, such as [A] year of partnership, [B] type of product, [D] type of partner, [E] most popular products, [F] most active industry players, [G] most active non-industry players and [H] geographical distribution of partnership activity.

Funding and Investment Analysis: An in-depth analysis of the fundings raised by companies that have proprietary T-cell based products/technologies, based on relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested (USD million), [D] type of therapy, [E] type of investor, [F] most active players, [G] most active investors, and [H] geography.

Patents Analysis: An in-depth analysis of patents filed / granted till 2022 related to CAR-Ts, TCRs and TILs, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] geographical distribution, [D] Cooperative Patent Classification (CPC) symbols, [E] emerging focus areas, [F] type of applicant, [G] leading players, [H] patent benchmarking, and [I] patent valuation analysis.

Other T-Cell Immunotherapies: An overview on other T-cell-based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, which are analyzed based on various parameters, such as [A] phase of development, [B] target therapeutic area(s), [C] type of T-cells used, [D] and source of T-cells.

Case Study: A detailed assessment of manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space. It provides information about these manufacturers, focusing on details of [A] scale of operation, [B] compliance with cGMP standards, [C] location of the manufacturing facility, and [D] products being manufactured.

Cost-Price Analysis: A detailed analysis of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.

Promotional Analysis: A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapy (Kimmtrak®).

Company Profiles: In-depth profiles of several developers evaluating T-cell immunotherapy therapies for the treatment of various oncological and non-oncological indications, focusing on [A] company overviews, [B] financial information (if available), [C] T-cell therapy (CAR-T, TCR and TIL) specific portfolio, [D] technology portfolio (if available), [E] manufacturing capabilities (if available), [F] recent collaborations , and [G] funding and investments received by the company related to T-cell immunotherapies.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What factors are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

What kind of partnership models are commonly adopted by industry stakeholders?

What is the ongoing investment trend in this market?

What is the patent filing activity trend in the market?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.